[HTML][HTML] A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate …
E Nicastri, F Marinangeli, E Pivetta, E Torri… - …, 2022 - thelancet.com
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID …
E Nicastri, F Marinangeli, E Pivetta… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
[HTML][HTML] A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate …
E Nicastri, F Marinangeli, E Pivetta, E Torri, F Reggiani… - eClinicalMedicine, 2022 - Elsevier
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
[引用][C] A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate …
E Nicastri, F Marinangeli, E Pivetta, E Torri… - …, 2022 - iris.hunimed.eu
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the
efficacy and safety of raloxifene for patients with mild to moderate COVID-19 IRIS IRIS Home …
efficacy and safety of raloxifene for patients with mild to moderate COVID-19 IRIS IRIS Home …
[HTML][HTML] A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate …
E Nicastri, F Marinangeli, E Pivetta, E Torri… - …, 2022 - ncbi.nlm.nih.gov
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID …
E Nicastri, F Marinangeli, E Pivetta, E Torri… - …, 2022 - iris.unito.it
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID …
E Nicastri, F Marinangeli, E Pivetta, E Torri, F Reggiani… - 2022 - cabidigitallibrary.org
Background: Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID …
E Nicastri, F Marinangeli, E Pivetta, E Torri… - …, 2022 - europepmc.org
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
[PDF][PDF] A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate …
E Nicastri, F Marinangeli, E Pivetta, E Torri… - 2022 - ingentium-kb4.s3.amazonaws.com
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
[PDF][PDF] A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate …
E Nicastri, F Marinangeli, E Pivetta, E Torri, F Reggiani… - 2022 - iris.unito.it
Background Current available therapeutic options for Coronavirus Disease-2019 (COVID-
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …
19) are primarily focused on treating hospitalized patients, and there is a lack of oral …